QQ客服 官方微博 反馈留言

	Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial
	Wang, Zhijie; Cheng, Ying; An, Tongtong; Gao, Hongjun; Wang, Kai; Zhou, Qing; Hu, Yanping; Song, Yong; Ding, Cuimin; Peng, Feng
刊名	LANCET RESPIRATORY MEDICINE
	2018
卷号	Vol.6 No.9页码:681-690
ISSN号	2213-2600
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/1834100
专题	四川大学
作者单位	1.Hebei Med Univ, Hosp 4, Dept Resp Med, Shijiazhuang, Hebei, Peoples R China 2.Tongji Univ, Shanghai Pulm Hosp, Shanghai, Peoples R China 3.AstraZeneca, IMED Asia, Shanghai, Peoples R China 4.Peking Union Med Coll, Beijing 100021, Peoples R China 5.Jilin Prov Canc Hosp, Div Thorac Oncol, Jilin Canc Hosp, Changchun, Jilin, Peoples R China 6.Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Resp Med, Hangzhou, Zhejiang, Peoples R China 7.Hubei Canc Hosp, Dept Oncol, Wuhan, Hubei, Peoples R China 8.Nanjing Gen Hosp Nanjing Mil Command, Nanjing, Jiangsu, Peoples R China 9.Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China 10.Peking Univ, Hosp 3, Beijing, Peoples R China
推荐引用方式 GB/T 7714	Wang, Zhijie,Cheng, Ying,An, Tongtong,et al. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial[J]. LANCET RESPIRATORY MEDICINE,2018,Vol.6 No.9:681-690.
APA	Wang, Zhijie.,Cheng, Ying.,An, Tongtong.,Gao, Hongjun.,Wang, Kai.,...&Peng, Feng.(2018).Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.LANCET RESPIRATORY MEDICINE,Vol.6 No.9,681-690.
MLA	Wang, Zhijie,et al."Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial".LANCET RESPIRATORY MEDICINE Vol.6 No.9(2018):681-690.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。